Function and regulation of serine/threonine phosphatases in the healthy and diseased heart

Journal of Molecular and Cellular Cardiology

Volumn 64, Issue , 2013, Pages 90-98

  Heijman, Jordi ^a   Dewenter, Matthias ^b   El Armouche, Ali ^b   Dobrev, Dobromir ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Atrial fibrillation; Dephosphorylation; Heart failure; Protein phosphatases

Indexed keywords

CALCIUM ION; CARDIAC PHOSPHATASE; CARDIAC PROTEIN; CELL PROTEIN; PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE; SERINE THREONINE PHOSPHATASE; UNCLASSIFIED DRUG;

CALCIUM CURRENT; CALCIUM TRANSPORT; CATALYSIS; CELL COMMUNICATION; COMPLEX FORMATION; DRUG TARGETING; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART FUNCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SUBUNIT; REGULATORY MECHANISM; REVIEW;

A-KINASE-ANCHORING PROTEIN; ACETYLCHOLINE-DEPENDENT INWARD-RECTIFIER K(+)-CURRENT; ACTION POTENTIAL; AF; AKAP; AP; ATRIAL FIBRILLATION; BASAL INWARD-RECTIFIER K(+)-CURRENT; CA(2+)/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE-II; CAMKII; CARDIAC MYOSIN-BINDING PROTEIN-C; CASEIN KINASE-2 INTERACTING PROTEIN-1; CKIP-1; CMYBP-C; DEPHOSPHORYLATION; HEART FAILURE; HF; I(CA,L); I(K,ACH); I(K1); I(KR); I(KS); I(KUR); I(NA); I(NAK); L-TYPE CA(2+)-CURRENT; NA(+)-CA(2+) EXCHANGER; NA(+)-CURRENT; NA(+)-K(+)-ATPASE CURRENT; NCX1; OA; OKADAIC ACID; PDE4D3; PHOSPHODIESTERASE-4D3; PHOSPHOLAMBAN; PKA; PKC; PLB; PP1; PP2A; PROTEIN KINASE-A; PROTEIN KINASE-C; PROTEIN PHOSPHATASE TYPE-1; PROTEIN PHOSPHATASE TYPE-2A; PROTEIN PHOSPHATASES; RAPID DELAYED-RECTIFIER K(+)-CURRENT; RYANODINE RECEPTOR TYPE-2; RYR2; SARCOPLASMIC RETICULUM; SARCOPLASMIC RETICULUM CA(2+)-ATPASE; SERCA2A; SLOW DELAYED-RECTIFIER K(+)-CURRENT; SR; TNI; TROPONIN-I; ULTRA-RAPID DELAYED-RECTIFIER K(+)-CURRENT; Β-ADRENOCEPTOR; Β-AR;

ANIMALS; ARRHYTHMIAS, CARDIAC; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HEART; HEART DISEASES; HUMANS; MYOCARDIAL CONTRACTION; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHORYLATION;

EID: 84884697675     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.09.006     Document Type: Review

References (96)

1. Fischer E.H., Krebs E.G. Conversion of phosphorylase b to phosphorylase a in muscle extracts. J Biol Chem 1955, 216:121-132.
2. Cohen P. The origins of protein phosphorylation. Nat Cell Biol 2002, 4:E127-E130.
3. Katz A.M., Tada M., Kirchberger M.A. Control of calcium transport in the myocardium by the cyclic AMP-protein kinase system. Adv Cyclic Nucleotide Res 1975, 5:453-472.
4. Hornbeck P.V., Kornhauser J.M., Tkachev S., Zhang B., Skrzypek E., Murray B., et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res 2012, 40:D261-D270.
5. Shi Y. Serine/threonine phosphatases: mechanism through structure. Cell 2009, 139:468-484.
6. Virshup D.M., Shenolikar S. From promiscuity to precision: protein phosphatases get a makeover. Mol Cell 2009, 33:537-545.
7. Ingebritsen T.S., Cohen P. Protein phosphatases: properties and role in cellular-regulation. Science 1983, 221:331-338.
8. Herzig S., Neumann J. Effects of serine/threonine protein phosphatases on ion channels in excitable membranes. Physiol Rev 2000, 80:173-210.
9. El-Armouche A., Eschenhagen T. Beta-adrenergic stimulation and myocardial function in the failing heart. Heart Fail Rev 2009, 14:225-241.
10. Cohen P. The structure and regulation of protein phosphatases. Annu Rev Biochem 1989, 58:453-508.
11. 2+ cycling. Cardiovasc Res 2011, 89:79-88.
12. Heroes E., Lesage B., Gornemann J., Beullens M., Van Meervelt L., Bollen M. The PP1 binding code: a molecular-lego strategy that governs specificity. FEBS J 2013, 280:584-595.
13. Cohen P.T. Protein phosphatase 1-targeted in many directions. J Cell Sci 2002, 115:241-256.
14. DeGrande S.T., Little S.C., Nixon D.J., Wright P., Snyder J., Dun W., et al. Molecular mechanisms underlying cardiac protein phosphatase 2A regulation in heart. J Biol Chem 2013, 288:1032-1046.
15. Ellinghaus P., Scheubel R.J., Dobrev D., Ravens U., Holtz J., Huetter J., et al. Comparing the global mRNA expression profile of human atrial and ventricular myocardium with high-density oligonucleotide arrays. J Thorac Cardiovasc Surg 2005, 129:1383-1390.
16. Lüss H., Klein-Wiele O., Boknik P., Herzig S., Knapp J., Linck B., et al. Regional expression of protein phosphatase type 1 and 2A catalytic subunit isoforms in the human heart. J Mol Cell Cardiol 2000, 32:2349-2359.
17. Wang Y., Tandan S., Hill J.A. Calcineurin-dependent ion channel regulation in heart. Trends Cardiovasc Med 2013, [in press]. 10.1016/j.tcm.2013.05.004.
18. Marionneau C., Lichti C.F., Lindenbaum P., Charpentier F., Nerbonne J.M., Townsend R.R., et al. Mass spectrometry-based identification of native cardiac Nav1.5 channel alpha subunit phosphorylation sites. J Proteome Res 2012, 11:5994-6007.
19. + channel function in epicardial border zone cells that survive in the infarcted canine heart?. Cardiovasc Res 2004, 64.
20. + channel I-II loop mediates parallel genetic and phosphorylation-dependent gating changes. Circulation 2012, 126:2042-2046.
21. Chen T.C., Law B., Kondratyuk T., Rossie S. Identification of soluble protein phosphatases that dephosphorylate voltage-sensitive sodium channels in rat brain. J Biol Chem 1995, 270:7750-7756.
22. Ks upregulation in human long-QT syndrome type 1. Circ Res 2012, 110:211-219.
23. Marx S.O., Kurokawa J., Reiken S., Motoike H., D'Armiento J., Marks A.R., et al. Requirement of a macromolecular signaling complex for beta adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel. Science 2002, 295:496-499.
24. El-Armouche A., Wittkopper K., Fuller W., Howie J., Shattock M.J., Pavlovic D. Phospholemman-dependent regulation of the cardiac Na/K-ATPase activity is modulated by inhibitor-1 sensitive type-1 phosphatase. FASEB J 2011, 25:4467-4475.
25. Bhasin N., Cunha S.R., Mudannayake M., Gigena M.S., Rogers T.B., Mohler P.J. Molecular basis for PP2A regulatory subunit B56α targeting in cardiomyocytes. Am J Physiol Heart Circ Physiol 2007, 293:H109-H119.
26. + current in human atrial myocytes. Circ Res 1996, 78:903-915.
27. + currents in canine ventricular cardiomyocytes. Br J Pharmacol 2011, 162:890-896.
28. Voigt N., Friedrich A., Bock M., Wettwer E., Christ T., Knaut M., et al. Differential phosphorylation-dependent regulation of constitutively active and muscarinic receptor-activated IK, ACh channels in patients with chronic atrial fibrillation. Cardiovasc Res 2007, 74:426-437.
29. v1.2. Biochemistry 2010, 49:10298-10307.
30. Hall D.D., Feekes J.A., Arachchige Don A.S., Shi M., Hamid J., Chen L., et al. Binding of protein phosphatase 2A to the L-type calcium channel Cav1.2 next to Ser 1928, its main PKA site, is critical for Ser1928 dephosphorylation. Biochemistry 2006, 45:3448-3459.
31. Marks A.R., Marx S.O., Reiken S. Regulation of ryanodine receptors via macromolecular complexes: a novel role for leucine/isoleucine zippers. Trends Cardiovasc Med 2002, 12:166-170.
32. Belevych A.E., Sansom S.E., Terentyeva R., Ho H.T., Nishijima Y., Martin M.M., et al. MicroRNA-1 and -133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 complex. PLoS One 2011, 6:e28324.
33. 2+ release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56α and causing CaMKII-dependent hyperphosphorylation of RyR2. Circ Res 2009, 104:514-521.
34. Dodge-Kafka K.L., Bauman A., Mayer N., Henson E., Heredia L., Ahn J., et al. cAMP-stimulated protein phosphatase 2A activity associated with muscle A kinase-anchoring protein (mAKAP) signaling complexes inhibits the phosphorylation and activity of the cAMP-specific phosphodiesterase PDE4D3. J Biol Chem 2010, 285:11078-11086.
35. Aye T.T., Soni S., van Veen T.A., van der Heyden M.A., Cappadona S., Varro A., et al. Reorganized PKA-AKAP associations in the failing human heart. J Mol Cell Cardiol 2012, 52:511-518.
36. Schulze D.H., Muqhal M., Lederer W.J., Ruknudin A.M. Sodium/calcium exchanger (NCX1) macromolecular complex. J Biol Chem 2003, 278:28849-28855.
37. 2+ exchanger 1 protein is not phosphorylated by protein kinase A". Am J Physiol Cell Physiol 2011, 300:C970-C973.
38. Solaro R.J., Kobayashi T. Protein phosphorylation and signal transduction in cardiac thin filaments. J Biol Chem 2011, 286:9935-9940.
39. Kuster D.W., Bawazeer A.C., Zaremba R., Goebel M., Boontje N.M., van der Velden J. Cardiac myosin binding protein C phosphorylation in cardiac disease. J Muscle Res Cell Motil 2012, 33:43-52.
40. Kooij V., Holewinski R.J., Murphy A.M., Van Eyk J.E. Characterization of the cardiac myosin binding protein-C phosphoproteome in healthy and failing human hearts. J Mol Cell Cardiol 2013, 60:116-120.
41. Yin X., Cuello F., Mayr U., Hao Z., Hornshaw M., Ehler E., et al. Proteomics analysis of the cardiac myofilament subproteome reveals dynamic alterations in phosphatase subunit distribution. Mol Cell Proteomics 2010, 9:497-509.
42. Marquez-Rosado L., Solan J.L., Dunn C.A., Norris R.P., Lampe P.D. Connexin43 phosphorylation in brain, cardiac, endothelial and epithelial tissues. Biochim Biophys Acta 1818, 2012:1985-1992.
43. Ai X., Jiang A., Ke Y., Solaro R.J., Pogwizd S.M. Enhanced activation of p21-activated kinase 1 in heart failure contributes to dephosphorylation of connexin 43. Cardiovasc Res 2011, 92:106-114.
44. El-Armouche A., Rau T., Zolk O., Ditz D., Pamminger T., Zimmermann W.H., et al. Evidence for protein phosphatase inhibitor-1 playing an amplifier role in beta-adrenergic signaling in cardiac myocytes. FASEB J 2003, 17:437-439.
45. Singh A., Redden J.M., Kapiloff M.S., Dodge-Kafka K.L. The large isoforms of A-kinase anchoring protein 18 mediate the phosphorylation of inhibitor-1 by protein kinase A and the inhibition of protein phosphatase 1 activity. Mol Pharmacol 2011, 79:533-540.
46. El-Armouche A., Bednorz A., Pamminger T., Ditz D., Didie M., Dobrev D., et al. Role of calcineurin and protein phosphatase-2A in the regulation of phosphatase inhibitor-1 in cardiac myocytes. Biochem Biophys Res Commun 2006, 346:700-706.
47. Wittkopper K., Fabritz L., Neef S., Ort K.R., Grefe C., Unsold B., et al. Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging. J Clin Invest 2010, 120:617-626.
48. Li M., Satinover D.L., Brautigan D.L. Phosphorylation and functions of inhibitor-2 family of proteins. Biochemistry 2007, 46:2380-2389.
49. Nicolaou P., Kranias E.G. Role of PP1 in the regulation of Ca cycling in cardiac physiology and pathophysiology. Front Biosci 2009, 14:3571-3585.
50. Qian J., Vafiadaki E., Florea S.M., Singh V.P., Song W., Lam C.K., et al. Small heat shock protein 20 interacts with protein phosphatase-1 and enhances sarcoplasmic reticulum calcium cycling. Circ Res 2011, 108:1429-1438.
51. Fetrow J.S., Siew N., Skolnick J. Structure-based functional motif identifies a potential disulfide oxidoreductase active site in the serine/threonine protein phosphatase-1 subfamily. FASEB J 1999, 13:1866-1874.
52. Honkanen R.E. Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Lett 1993, 330:283-286.
53. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Borden W.B., et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013, 127:e6-e245.
54. Nattel S., Maguy A., Le Bouter S., Yeh Y.H. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev 2007, 87:425-456.
55. Wijnker P.J., Boknik P., Gergs U., Muller F.U., Neumann J., dos Remedios C., et al. Protein phosphatase 2A affects myofilament contractility in non-failing but not in failing human myocardium. J Muscle Res Cell Motil 2011, 32:221-233.
56. El-Armouche A., Pamminger T., Ditz D., Zolk O., Eschenhagen T. Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts. Cardiovasc Res 2004, 61:87-93.
57. Dobrev D. Electrical remodeling in atrial fibrillation. Herz 2006, 31:108-112. [quiz 42-3].
58. Nattel S., Burstein B., Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 2008, 1:62-73.
59. Heijman J., Voigt N., Dobrev D. New directions in antiarrhythmic drug therapy for atrial fibrillation. Future Cardiol 2013, 9:71-88.
60. 2+ current downregulation in chronic human atrial fibrillation is associated with increased activity of protein phosphatases. Circulation 2004, 110:2651-2657.
61. 2+ handling in human chronic atrial fibrillation. Circulation 2006, 114:670-680.
62. Greiser M., Halaszovich C.R., Frechen D., Boknik P., Ravens U., Dobrev D., et al. Pharmacological evidence for altered src kinase regulation of ICa, L in patients with chronic atrial fibrillation. Naunyn Schmiedebergs Arch Pharmacol 2007, 375:383-392.
63. Yeh Y.H., Wakili R., Qi X.Y., Chartier D., Boknik P., Kaab S., et al. Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. Circ Arrhythm Electrophysiol 2008, 1:93-102.
64. Greiser M., Neuberger H.R., Harks E., El-Armouche A., Boknik P., de Haan S., et al. Distinct contractile and molecular differences between two goat models of atrial dysfunction: AV block-induced atrial dilatation and atrial fibrillation. J Mol Cell Cardiol 2009, 46:385-394.
65. Wakili R., Yeh Y.H., Yan Qi X., Greiser M., Chartier D., Nishida K., et al. Multiple potential molecular contributors to atrial hypocontractility caused by atrial tachycardia remodeling in dogs. Circ Arrhythm Electrophysiol 2010, 3:530-541.
66. Ai X., Pogwizd S.M. Connexin 43 downregulation and dephosphorylation in nonischemic heart failure is associated with enhanced colocalized protein phosphatase type 2A. Circ Res 2005, 96:54-63.
67. Remo B.F., Qu J., Volpicelli F.M., Giovannone S., Shin D., Lader J., et al. Phosphatase-resistant gap junctions inhibit pathological remodeling and prevent arrhythmias. Circ Res 2011, 108:1459-1466.
68. Qi X.Y., Yeh Y.H., Xiao L., Burstein B., Maguy A., Chartier D., et al. Cellular signaling underlying atrial tachycardia remodeling of L-type calcium current. Circ Res 2008, 103:845-854.
69. Makary S., Voigt N., Maguy A., Wakili R., Nishida K., Harada M., et al. Differential protein kinase C isoform regulation and increased constitutive activity of acetylcholine-regulated potassium channels in atrial remodeling. Circ Res 2011, 109:1031-1043.
70. Marx S.O., Reiken S., Hisamatsu Y., Jayaraman T., Burkhoff D., Rosemblit N., et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 2000, 101:365-376.
71. 2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circulation 2012, 125:2059-2070.
72. Lymperopoulos A., Rengo G., Funakoshi H., Eckhart A.D., Koch W.J. Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med 2007, 13:315-323.
73. El-Armouche A., Pohlmann L., Schlossarek S., Starbatty J., Yeh Y.H., Nattel S., et al. Decreased phosphorylation levels of cardiac myosin-binding protein-C in human and experimental heart failure. J Mol Cell Cardiol 2007, 43:223-229.
74. Wittkopper K., Dobrev D., Eschenhagen T., El-Armouche A. Phosphatase-1 inhibitor-1 in physiological and pathological beta-adrenoceptor signalling. Cardiovasc Res 2011, 91:392-401.
75. Dobrev D., Carlsson L., Nattel S. Novel molecular targets for atrial fibrillation therapy. Nat Rev Drug Discov 2012, 11:275-291.
76. Heineke J., Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006, 7:589-600.
77. Bukowska A., Lendeckel U., Hirte D., Wolke C., Striggow F., Rohnert P., et al. Activation of the calcineurin signaling pathway induces atrial hypertrophy during atrial fibrillation. Cell Mol Life Sci 2006, 63:333-342.
78. Ling S., Sun Q., Li Y., Zhang L., Zhang P., Wang X., et al. CKIP-1 inhibits cardiac hypertrophy by regulating class II histone deacetylase phosphorylation through recruiting PP2A. Circulation 2012, 126:3028-3040.
79. Carr A.N., Schmidt A.G., Suzuki Y., del Monte F., Sato Y., Lanner C., et al. Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol 2002, 22:4124-4135.
80. Nicolaou P., Hajjar R.J., Kranias E.G. Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology. J Mol Cell Cardiol 2009, 47:365-371.
81. El-Armouche A., Wittkopper K., Degenhardt F., Weinberger F., Didie M., Melnychenko I., et al. Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy. Cardiovasc Res 2008, 80:396-406.
82. Pathak A., del Monte F., Zhao W., Schultz J.E., Lorenz J.N., Bodi I., et al. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res 2005, 96:756-766.
83. Grote-Wessels S., Baba H.A., Boknik P., El-Armouche A., Fabritz L., Gillmann H.J., et al. Inhibition of protein phosphatase 1 by inhibitor-2 exacerbates progression of cardiac failure in a model with pressure overload. Cardiovasc Res 2008, 79:464-471.
84. 2+ sensitivity of contraction and impairs cardiac function. Circ J 2010, 74:120-128.
85. Gergs U., Boknik P., Buchwalow I., Fabritz L., Matus M., Justus I., et al. Overexpression of the catalytic subunit of protein phosphatase 2A impairs cardiac function. J Biol Chem 2004, 279:40827-40834.
86. Brewis N., Ohst K., Fields K., Rapacciuolo A., Chou D., Bloor C., et al. Dilated cardiomyopathy in transgenic mice expressing a mutant A subunit of protein phosphatase 2A. Am J Physiol Heart Circ Physiol 2000, 279:H1307-H1318.
87. McConnell J.L., Wadzinski B.E. Targeting protein serine/threonine phosphatases for drug development. Mol Pharmacol 2009, 75:1249-1261.
88. Armstrong C.G., Doherty M.J., Cohen P.T. Identification of the separate domains in the hepatic glycogen-targeting subunit of protein phosphatase 1 that interact with phosphorylase a, glycogen and protein phosphatase 1. Biochem J 1998, 336(Pt 3):699-704.
89. Uehata M., Ishizaki T., Satoh H., Ono T., Kawahara T., Morishita T., et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997, 389:990-994.
90. Yger M., Girault J.A. DARPP-32, Jack of all trades... master of which?. Front Behav Neurosci 2011, 5:56.
91. Boyce M., Bryant K.F., Jousse C., Long K., Harding H.P., Scheuner D., et al. A selective inhibitor of eIF2α dephosphorylation protects cells from ER stress. Science 2005, 307:935-939.
92. Tsaytler P., Harding H.P., Ron D., Bertolotti A. Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science 2011, 332:91-94.
93. Morishita W., Connor J.H., Xia H., Quinlan E.M., Shenolikar S., Malenka R.C. Regulation of synaptic strength by protein phosphatase 1. Neuron 2001, 32:1133-1148.
94. Yamada M., Ikeda Y., Yano M., Yoshimura K., Nishino S., Aoyama H., et al. Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy. FASEB J 2006, 20:1197-1199.
95. Miyazaki Y., Ikeda Y., Shiraishi K., Fujimoto S.N., Aoyama H., Yoshimura K., et al. Heart failure-inducible gene therapy targeting protein phosphatase 1 prevents progressive left ventricular remodeling. PLoS One 2012, 7:e35875.
96. Fish K.M., Ladage D., Kawase Y., Karakikes I., Jeong D., Ly H., et al. AAV9.I-1c delivered via direct coronary infusion in a porcine model of heart failure improves contractility and mitigates adverse remodeling. Circ Heart Fail 2013, 6:310-317.